Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma
✍ Scribed by Dr. David Shrayer; Hendrix Bogaars; Douglas Gersten; Vincent Hearing; Abby Maizel; Harold Wanebo
- Book ID
- 102926390
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 662 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
A model to study passive humoral immunotherapy of experimental nielanoma was generated by subcutaneous injection of B16 F10 murine melanoma cells in the midtail of BALBK nude (nuhu) mice. Mice were challenged with melanoma cells pretreated: (1) with complete culture medium, (2) with 10% adjuvant control serum, (3) with 10% anti-fECA (formalinized extracellular antigens) immune serum, or (4) with a nionoclonal antibody (mAb H2-3-3) specific for the B700 melanoma-associated antigen. All control mice challenged with melanoma cells pretreated either with culture medium or with medium containing adjuvant control serum (Groups 1 and 11) died during the observation period of 84 days. At day 84, 60% of the mice challenged with melanoma cells pretreated with anii-tECA immune serum (Group Ill) survived, as did 100% of the mice challenged with cells pretreated with mAb H2-3-3 (Group IV). Injection of melanoma cells pretreated with mAb H2-3-3 was associated with the greatest reduction of subsequent local tumor growth and the lowest number of metastatic lung tumors. The inhibitory effects of immune sera in viko also correlated with in vitro effects of anti-fECA immune serum and mAb H2-3-3. determined on B16 FIO melanoma target cells using assays for DNA synthesis and antibody dependant cellular cytotoxicity (ADCC). In sum, this nude mouse model for the study of passive humoral immunotherapy of experimental melanoma was utilized to demonstrate significant protective effects against B 16 FIO melanoma cell challenge by treatment with anti-fECA immune sera or a melanoma-specific monoclonal antibody.